Geron

Geron EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Geron (GERN) as of Nov 7, 2026 is -19.83. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.06 — a change of 227.02% (lower).

EV/EBIT

-19.83

YoY

227.02%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Geron is 2025 -19.83 . EV/EBIT (Enterprise Value to EBIT) of Geron was 2024 -6.06 . It decreases by 227.02% lower compared to the previous year.

The Geron EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-14.53 USD
Jan 1, 2020
-13.69 USD
Jan 1, 2021
-9.33 USD
Jan 1, 2022
-7.66 USD
Jan 1, 2023
-5.43 USD
Jan 1, 2024
-6.06 USD
Jan 1, 2025
-19.83 USD
Jan 1, 2026 (e)
-65.89 USD
The Geron EV/EBIT history
YEAREV/EBITYoY
est-65.89+232.33%
-19.83+227.02%
-6.06+11.63%
-5.43-29.08%
-7.66-17.92%
-9.33-31.87%
-13.69-5.73%
-14.53-57.14%
-33.90-5.85%
-36.00+4.75%
-34.37-98.18%
-1,884.23+6,395.89%
-29.01+1,281.26%
-2.10+517.65%
-0.34+209.09%
-0.11-59.26%
-0.27-35.71%
-0.42+27.27%
-0.33-17.50%
-0.40-45.21%
-0.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geron Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Geron's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Geron's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Geron's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Geron grows earnings faster than its peers.

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geron stock

EV/EBIT (Enterprise Value to EBIT) of Geron is -19.83 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Geron changed from -6.06 to -19.83, representing a 227.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Geron since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Geron with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Geron

All Key Metrics — Geron